Categories: News

Acceled, Formerly Penn Photon Devices, Announces its New cLight

Multi-Plate Irradiation to Speed Cellular Catalyst Research in Drug Discovery, Biochemistry

PENNSBURG, Pa., June 16, 2022 /PRNewswire-PRWeb/ — Acceled LLC, providers of benchtop instruments designed for chemists and researchers seeking to accelerate chemical reactions using photoredox catalysis, announces today the introduction of the cLight. The cLight joins the Acceled Photoreactor product line to add versatility and functionality for biochemists. The cLight, ideal for drug discovery and university research, allows for:

  • Single or multi-plate catalysis experimentation
  • Uniform LED illumination and cooling in a single device
  • Enhanced statistical comparison between protein interaction networks
  • User-customized time, light intensity, and temperature
  • Faster, repeatable, comparable results

Acceled’s expanded product line now supports growth plates as well as vial sizes GC, 4, 8, 30, and 40 ml. This increased versatility and compact footprint allow for expanded experiment design and fit:

  • External dimensions: 18″ L x 11.375″ W x 6.7″ H
  • LED active area: 12.9″ x 8.6″
  • 4.3″ diagonal touch screen
  • “6-plex” dish at 90.5mm (3.56″) diameter holds up to six dishes
  • > 95% uniformity across working area of illumination

Biochemistry research must ramp up to meet the demands for innovation in genetic research, pharmaceuticals, proteomics, diagnostics, and food science. Acceled’s Photoreactor m2 and new cLight instruments support these aggressive innovation pipelines.

Prominent universities and top pharmaceutical companies around the world rely on Acceled’s photoreactor platform. The cLight is now available for order at acceledbio.com/cLight.

ABOUT ACCELED
The scientists and engineers behind Acceled are focused on bringing novel photocatalysis technology and products to researchers seeking to accelerate chemical reactions using photoredox catalysis. Their best-in-class tools support researchers and scientists dedicated to solving real-world challenges in drug discovery, pharma, proteomics, and basic material research. Learn more at https://www.acceledbio.com/.

Media Contact

Alison Arnold, Launch Team Inc, 1 (585) 256-1640, alison@launchteaminc.com

LinkedIn

 

SOURCE Acceled

Staff

Recent Posts

Unique Treatment for BPH, Chronic Prostatitis, Back Pain and Kidney Stones Was Unveiled at Arab Health 2024 by Ariana Adjani

* Efficacy, safety, and cost-effectiveness of Thermobalancing therapy and Dr Allen's Devices were showcased at…

21 hours ago

Financière de Tubize – Annual report 2023

FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: investorrelations@financiere-tubize.be Annual Report…

2 days ago

ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP…

2 days ago

Ibogaine By David Dardashti Leverages Albert Einstein’s Corelation Between Photon Particles and Quantum Electrodynamics

Ibogaine By David Dardashti Revolutionizes Solar Energy Efficiency Through Radiation Generators Einstein A young and…

2 days ago

Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM)…

2 days ago

NurExone’s Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

TORONTO and HAIFA, Israel, March 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX)…

2 days ago